Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 2/20 | 0.31 |
| ▸ | STK3 | Q13188 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223108 | 1.00 | MAPK14 (0.49) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL6218187 | 0.92 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL6220074 | 0.92 | MAPK11 (0.56) | MAPK14MAPK11RAF1GSK3BPARP1 | |
| SCHEMBL5764180 | 0.91 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5763781 | 0.90 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL6221125 | 0.90 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12GSK3B | |
| SCHEMBL6219051 | 0.90 | MAPK11 (0.52) | MAPK14MAPK11SLC9A1 | |
| SCHEMBL6219480 | 0.89 | MAPK11 (0.54) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL6391898 | 0.89 | MAPK11 (0.36) | MAPK14MAPK11SLC9A1STK4STK3 | |
| SCHEMBL5765704 | 0.88 | MAPK14 (0.51) | MAPK14MAPK11MAPK13MAPK12RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | claimed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | claimed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | claimed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK14 3902/4885MAPK11 3630/4885MAPK13 3723/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | MAPK14 4157/4885MAPK11 3723/4885MAPK13 3928/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | MAPK14 3593/4885MAPK11 3364/4885MAPK13 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.